Article
Genomewide Association Study of Platelet Reactivity and Cardiovascular Response in Patients Treated With Clopidogrel: A Study by the International Clopidogrel Pharmacogenomics Consortium.
Clinical pharmacology and therapeutics - 1 Nov 2020
Verma Shefali Setia, Bergmeijer Thomas O, Gong Li, Reny Jean-Luc, Lewis Joshua P, Mitchell Braxton D, Alexopoulos Dimitrios, Aradi Daniel, Altman Russ B, Bliden Kevin, Bradford Yuki, Campo Gianluca, Chang Kiyuk, Cleator John H, Déry Jean-Pierre, Dridi Nadia P, Fernandez-Cadenas Israel, Fontana Pierre, Gawaz Meinrad, Geisler Tobias, Gensini Gian Franco, Giusti Betti, Gurbel Paul A, Hochholzer Willibald, Holmvang Lene, Kim Eun-Young, Kim Ho-Sook, Marcucci Rossella, Montaner Joan, Backman Joshua D, Pakyz Ruth E, Roden Dan M, Schaeffeler Elke, Schwab Matthias, Shin Jae Gook, Siller-Matula Jolanta M, Ten Berg Jurriën M, Trenk Dietmar, Valgimigli Marco, Wallace John, Wen Ming-Shien, Kubo Michiaki, Lee Ming Ta Michael, Whaley Ryan, Winter Stefan, Klein Teri E, Shuldiner Alan R, Ritchie Marylyn D
Abstract excerpt
Antiplatelet response to clopidogrel shows wide variation, and poor response is correlated with adverse clinical outcomes. CYP2C19 loss-of-function alleles play an important role in this response, but account for only a small proportion of variability in response to clopidogrel. An aim of the International Clopidogrel Pharmacogenomics Consortium (ICPC) is to identify other genetic determinants of clopidogrel...
Read the complete abstract on PubMed